pharmaphorum

OCTOBER 4, 2020

However it requires high-dose chemotherapy to destroy the bone marrow, and that poses significant risks to patients in its own right, and can also lead to graft-versus-host disease, a potentially life-threatening complication in which the bone marrow donor’s immune cells attack the recipient’s cells and tissues.

Immunization 98

Immunization Chemotherapy FDA 98

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunization 95

Immunization Chemotherapy FDA Pharmaceutical Companies 95

European Pharmaceutical Review

DECEMBER 28, 2023

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

European Pharmaceutical Review

JUNE 27, 2023

difficile infection by the end of 2024 and will be announcing first patient dosed in the Phase II clinical trial of VE202 for ulcerative colitis (UC) shortly too. How do you envision microbiome therapies complementing existing cancer treatments, such as chemotherapy and immunotherapy?

Chemotherapy 105

Chemotherapy Immunization FDA Vaccines 105

PQA

NOVEMBER 1, 2024

We are excited to host members next week at the 2024 PQA Leadership Summit and PQA Convenes: Quality Medication Use in Rare Disease at the Renaissance Arlington Capital View Hotel in Arlington, Va. Thank you to our 2024 PQA Leadership Summit sponsors! There is still time for members to join us at both events!

Specialty Pharmacies 52

Specialty Pharmacies Vaccines Chemotherapy Immunization 52

Hospital Pharmacy Europe

OCTOBER 14, 2024

On 31 May 2024, Dr Kunene led a team to administer the very first personalised vaccine against colorectal cancer in England as part of the pioneering NHS Cancer Vaccine Launch Pad (CVLP) initiative. Of course, we’ve also had the advent of immune checkpoint inhibitors.

Vaccines 52

Vaccines Chemotherapy Hospitals Immunization 52

Hospital Pharmacy Europe

FEBRUARY 15, 2024

They are] administered by the same nurses who would normally give chemotherapy’, Dr Tucker says. Other potential barriers lie in the risks associated with stimulation of the immune system, which we also need for these agents to work’, Dr Walter continues.

Chemotherapy 52

Chemotherapy Hospitals Immunization Vaccines 52

PharmaShots

MARCH 29, 2023

It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. According to the Novo Nordisk legal settlement with its competitors, though the Victoza patent expires in 2023, the drug wouldn’t face generic competition until 2024.

FDA 49

FDA Chemotherapy Immunization Dosage 49

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Accessed September 6, 2024. Accessed September 17, 2024. freece.com. [11] 11] Bhattacharjee B, Upadhyay S, Ghosh J.

Health and Personal Care Stores 75

Health and Personal Care Stores Chemotherapy Immunization Compounding 75

Blog: Ask a Student Pharmacist

JUNE 21, 2023

Particularly, we devote a large portion of our research to identifying novel compounds that impact cellular uptake or inhibit drug efflux - the most common mechanism underlying acquired drug resistance in cancer, pinpointing the transporters or targets involved in these processes, and evaluating regimens to produce desirable anti-cancer responses.

Compounding 40

Compounding Chemotherapy Immunization 40

European Pharmaceutical Review

FEBRUARY 3, 2025

Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy. The EC questioned whether this would necessitate an update of the CHMPs opinion made in November 2024.

Generic Medicine 52

Generic Medicine Vaccines Chemotherapy Immunization 52